Global Entry into the Biosimilars Business
First written in FY2018. 4 of 10 entries say "Restated". Latest entry: 2026-08-13.
No other company in this theme has enough history to compare yet.
- FY2026SoftenedAnnual report
「For new biosimilars in particular, discussions are already under way with multiple domestic and overseas pharmaceutical companies that are potential partners for joint commercialization, based on global expansion.」
Discussions with potential domestic and overseas partners for global expansion are continuing, but this filing does not state the previously indicated deadline of the end of September 2025 for concluding agreements. - 2026-05-14RestatedEarnings presentation
「We aim to develop a biopharmaceutical CDMO business, including the commercial manufacture of novel biosimilars, while pursuing the global expansion of the biosimilars business.」
The development of a domestic manufacturing facility and global expansion of the biosimilars business are presented as an integrated growth initiative. - FY2025AdvancedAnnual report
「For new biosimilars, the Company is already holding discussions under confidentiality agreements with multiple domestic and overseas pharmaceutical companies that are potential partners, and aims to conclude joint commercialization agreements and other agreements by the end of September 2025 with a view to expanding the business in overseas markets.」
Regarding global entry by the biosimilar business, the Company presented development plans for new products, discussions with multiple domestic and overseas pharmaceutical companies, and a target of concluding joint commercialization agreements by the end of September 2025. - FY2025-H1AdvancedAnnual report
「In parallel with already fleshing out development plans for the Group's fifth and subsequent products under the business alliance, the Company is holding discussions with multiple domestic and overseas pharmaceutical companies and others under confidentiality agreements, and aims to conclude joint commercialization agreements and other agreements at an early date with a view to expanding the business in overseas markets.」
Regarding global entry by the biosimilar business, the Company has moved to the stage of fleshing out development plans for the fifth and subsequent products and holding discussions with domestic and overseas pharmaceutical companies. - FY2022RaisedAnnual report
「Meanwhile, with the aim of expanding the business going forward, the Company is considering and pursuing the addition of indications for the product under development in Japan and overseas expansion into markets with greater potential.」
Regarding the goal of global entry by the biosimilar business, the Company identifies adding indications for the ranibizumab biosimilar in Japan and expanding overseas into larger markets as specific expansion measures. - FY2020RestatedAnnual report
「The company aims to enter the biosimilars field globally, as the global market for a single biologic can be worth several hundred billion yen and healthcare authorities in various countries are raising their requirements for generic products.」
Reconfirms the goal of entering global markets through the biosimilar business as a whole. - FY2019RestatedAnnual report
「The company aims to enter the biosimilars field globally, as the global market for a single biologic can be worth several hundred billion yen and healthcare authorities in various countries are raising their requirements for generic products.」
Reconfirms the goal of entering global markets through the biosimilar business as a whole. - FY2018First statedAnnual report
「The company aims to enter the biosimilars field globally, as the global market for a single biologic can be worth several hundred billion yen and healthcare authorities in various countries are raising their requirements for generic products.」
The goal of entering global markets was explicitly stated for the biosimilar business as a whole, rather than for an individual filgrastim product, for the first time.